Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saba Sile

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Lancet (London, England)|April 19, 2014
Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trialNicola Longo, Cary O Harding, Barbara K Burton, et al.
Ophthalmology|October 24, 2021
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X StudyRaymond S Douglas, George J Kahaly, Shoaib Ugradar, et al.
The New England Journal of Medicine|January 24, 2020
Teprotumumab for the Treatment of Active Thyroid Eye DiseaseRaymond S Douglas, George J Kahaly, Amy Patel, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Lancet (London, England)|April 19, 2014
Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trialNicola Longo, Cary O Harding, Barbara K Burton, et al.
Ophthalmology|October 24, 2021
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X StudyRaymond S Douglas, George J Kahaly, Shoaib Ugradar, et al.
The New England Journal of Medicine|January 24, 2020
Teprotumumab for the Treatment of Active Thyroid Eye DiseaseRaymond S Douglas, George J Kahaly, Amy Patel, et al.
Pageof 2